Principal Investigator/Program Director (Last, First, Middle):
BIOGRAPHICAL SKETCH Provide the following information for the key personnel in the order listed on Form Page 2.  Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME Satish Garg, MD		POSITION TITLE Professor of Medicine & Pediatrics, Director, Young Adult Clinic, The Barbara Davis Center for Childhood Diabetes.  University of Colorado, School of Medicine, Aurora, CO.
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION	DEGREE (if applicable)		YEAR(s)	FIELD OF STUDY
Christian Medical College & Hospital	MBBS		1975	Medical School
PunjabUniversity, Ludhiana, India	MD		1979	Internal Medicine
PGIMER, Chandigarh, India	DM		1982	Endocrinology

A. Positions and Honors

 
 

Professional Experience:

1980-82 Endocrine/Diabetes Fellow   PGIMER, Chandigarh

1983-85 Assistant Professor    PGIMER, Chandigarh

1987-88 Associate Professor    PGIMER, Chandigarh

1989-91 Diabetes Fellow     University of Colorado, Dept. of Pediatrics

1992-99 Associate Professor    University of Colorado Health Sciences Ctr.

      Director of Adult Clinic    Barbara Davis Center for Childhood Diabetes

1999-present     Professor of Medicine & Pediatrics  University of Colorado Health Sciences Ctr.

      Director of Adult Clinic    Barbara Davis Center for Childhood Diabetes

Honors and Awards:

Editorial Board for Diabetes Technology & Therapeutics journal

Reviewer for Diabetes, Diabetes Care, Endocrine Practice, Pediatric Endocrinology, Metabolism, Diabetologia, and Diabetic Medicine

Editorial Board, Diabetes Bulletin

Medical Director of Diabetes Camps in India

Member of Executive Committee of JDF in India

Regional Director of Iodine Def. Goitre in India

Fellow at University of Colorado Health Sciences Center, Denver, CO.

Invited lectures for ADA, EASD, IDF,  Academic Institutional Endocrine and Medicine Grand Rounds, Global and National Speaker Bureau for Eli Lilly & Co and MiniMed. Inc., Lifescan, Takeda Pharmaceuticals, DexCom, Sanofi-Aventis, Inc. Novo Nordisk, Pfizer, and CME Programs.

B. Selected Peer Reviewed Publications

Chase HP, Jackson WE, Lockspeiser T, Garg SK:  Angiotensin Converting Enzyme-Inhibitor Treatment and Microvascular Complications of Type I Diabetes.  Accepted for publication in Journal of Diabetes and Its Complications, 1998.

Brewer KW, Owen S, Garg SK, Chase HP:  Slicing the Pie:  Correlating Hemoglobin A1c (HbA1c) values with average blood glucose (ABG) values in a pie chart form.  Diabetes Care, 21:209-212, 1998.

Travaglini MT, Garg SK, Chase HP:  Use of Insulin-Lispro (Humalogā) in the Outpatient Management of Ketonuria. Archives of Pediatric and Adolescent Medicine, 152:672-675, 1998.

Garg SK, Jackson WE, Chase HP, Rothman RL, Carmain JA, Icaza G:  Diabetic Retinopathy and 24-hour Ambulatory Blood Pressure Monitoring in Young Subjects with Type I Diabetes.  Ann Ophthalmol, 31(4/5):233-237, 1999.

Garg S, Anderson J, Perry S, MacKenzie T, Keith P, Hansen M, Jennings M, Chase H:  Long-term efficacy of Humalog in subjects with type 1 diabetes.  Diabetic Medicine, 16:384-387, 1999.

Rewers M, Ehrlich J, Jensen L, Seigel R, Barriga K, Garg S, Janowitz W, Eckel R:  High prevalence of asymptomatic coronary atherosclerosis detected by electron beam computed tomography in young adults with IDDM.  Diabetes, 47:12, 1998.

Garg SK, Chase HP, Pennington LM, Hiar CE:  Comparison of albumin levels in 24 hour, timed overnight, and spot urine samples in type 1 diabetes.  Diabetes, 47:128, 1998.

Redondo MJ, Rewers M, Yu L, Garg SK, Eisenbarth GS:  Anti-islet autoimmunity is mainly genetically determined: analysis of monozygotic twins, dizygotic twins and siblings of patients with type 1 diabetes.  Diabetes, 47:204, 1998.

Garg S, Gerard L, Pennington M, Mecca T, Taylor L, Chase P, Jennings K:  Efficacy of the new long acting insulin analog (HOE901) on fasting glucose values in IDDM.  Diabetes, 47:359, 1998.

Garg S, Anderson J, Perry S, Jennings K, Keith P, Chase P:  Long term efficacy of Humalog in decreasing postprandial glucose excursions in type 1 diabetes.  Diabetes, 47:360, 1998.

Chase HP, Garg SK: 24-hour ambulatory blood pressure monitoring in Type 1 Diabetes. Practical Diabetology,18:17-19, 1999.

Garg SK, Chase HP, Jackson We, Rothman RL, Carmain JA, Icaza G.  Diabetic retinopathy and 24-hour ambulatory blood pressure monitoring in young subjects with type 1 diabetes.  Ann Ophthalmol 31:233-237, 1999.

Garg SK, Potts RO, Ackerman NR, Fermi SJ, Tamada JA, Chase HP:  Correlation of fingerstick blood glucose measurements with GlucoWatch Biographer results in young subjects with type 1 diabetes.  Diabetes Care, 22:1708-1714, 1999.

Redondo MJ, Rewers M, Jackson R, Yu L, Garg S, Pilcher CC, Elliott RB, Eisenbarth GS:  Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study.  British Medical Journal, 318:698-702, 1999.

Tamada JA, Garg S, Jovanovic L, Fermi S, Potts RO, Cygnus Research Team:  Non-invasive glucose monitoring:  comprehensive clinical results.  JAMA, 282:1839-1844, 1999.

Branson B, Garg SK, Goode JR, Phillips KA, Small RE, LoBuono C:  Taking advantage of home testing and monitoring.  Patient Care, 144-152, 2000.

Garg SK, Anderson JH, MacKenzie TA, Gerard LA, Gottlieb PA, Jennings MK, Chase HP:  Impact of Humalog insulin on HbA1c values in insulin pump users.  Diabetes, Obesity, and Metabolism, 2:307-311, 2000.

Ratner RE, Hirsh IB, Neifing JL, Garg SK, Mecca TE, Wilson CA:  Less hypoglycemia with Insulin Glargine (HOE901) in Intensive Insulin Therapy for Type 1 Diabetes.  Diabetes Care, 23:639-643, 2000.

Tierney, MJ, Garg S, Ackerman NR, Potts RO, Pitzer K, Tamada JA, Fermi SJ:  Effect of acetaminophen on the accuracy of glucose measurements obtained with the GlucoWatch Biographer.  Diabetes Technology & Therapeutics, 2:199-207, 2000.

Chase HP, Shephard M, Anderson JH, Garg SK:  The Impact of the Diabetes Control and Complications Trial and Humalog Insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care, 24:430-434, 2001.

Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK:  Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics, 107:222-226, 2001.

Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg SK, and the Cygnus Research Team:  Clinical evaluation of the GlucoWatch Biographer:  A continual, non-invasive glucose monitor for patients with diabetes.  Biosensors and Bioelectronics, 16:621-629, 2001.

Johnston-Brooks CH, Lewis MA, Garg S:  Self-Efficacy impacts self-care and HbA1c in young adults with type 1 diabetes.  Psychosomatic Medicine, 64:43-51, 2002.

Chase HP, Saib SZ, MacKenzie T, Hansen MM, Garg SK:  Postprandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes.  Diabetic Medicine, 19:317-321, 2002.

Gottlieb PA, Frias JP, Peters KA, Chillara B, Garg SK:  Optimizing insulin therapy in pregnant women with type 1 diabetes mellitus.  Treat Endocrinol; 1:235-240, 2002.

Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, VanWyhe M, Desai S, Harper W, Lopatin M, Bartkowiak M, Tamada J, Eastman R,:  Use of the GlucoWatch Biographer in Children with Type 1 Diabetes.  Pediatrics,  111:790-794, 2003.

Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK:  Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine therapy.  Accepted for publication J Pediatr. ; 143:737-740,  2003.

Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE:  Insulin lispro therapy in pregnancies complicated by type 1 diabetes:  Glycemic control and maternal and fetal outcomes.  Endocrine Practice; 9:187-193, 2003.

Chase HP, Pearson G, Wightman C, Roberts M, Oderberg A, Garg SK:  Modem transmission of glucose values reduces cost and need for clinic visits.  Diabetes Care; 26:1-5, 2003.

Snell-Bergeon J, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg SK, Rewers M:  Progression of coronary artery calcification in type 1 diabetes:  The importance of glycemic control.  Diabetes Care, 26:2923-2928, 2003.

Dabelea D, Kinney G, Snell-Bergeon J, Hokanson JH, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M:  The effect of type 1 diabetes on the gender difference in coronary artery calcification:  A role for insulin resistance?   Diabetes Care, 52(11): 2833-2839, 2003.

Garg SK, Hoff HK, Chase HP:  The role of continuous glucose sensors in diabetes care.  Endocrinology & Metabolism Clinics of North America, 33:163-173, 2004.

Garg SK, Chase HP:  Letter to editor.  4005 study.  Journal of Pediatric Endocrinology and Metabolism, 17: 805-806, 2004.

Garg SK, Schwartz S, Edelman SV:  Improved glucose excursions using an implantable real-time continuous implanted glucose sensor in adults with type 1 diabetes.  Diabetes Care, 27:734-738, 2004.

Garg SK, Walker AJ, Hoff HK, D’Souza AO, Gottlieb PA, Chase HP:  Glycemic parameters with MDI using insulin glargine vs. insulin pump. Diabetes Technology & Therapeutics,  6:9-15, 2004.

Garg SK, Hisatomi ME, D’Souza A, Gottlieb PA, Walker AJ, Izuora KE, Chase HP:      Improved glycemic control using different glargine regimens in adults with type 1 diabetes.  Diabetes Research & Clinical Practice, 66:49-56, 2004.

Garg SK: Health Impact from Frequent and Continuous Glucose Monitoring, an Editorial, Diabetes technology and Therapeutics 6: 523-524, 2004.

Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technology and Therapeutics, 6:589-595, 2004. 

Wyatt JW, Frias JL, Hoyme HE, Jovanovic L, Kaaja R, Brown F, Garg S, Lee-Parritz A, Kerr   L, Mattoo V, Tan M, IONS Study Group:  Congenital anomaly rate in neonates of mothers with pregestational diabetes treated with insulin lispro during pregnancy.  Diabetic Medicine, 22:803-807, 2005.

Garg SK, Carter JA, Mullen L, Folker AC, Parkes JL, Tideman AM:  The clinical performance and ease of use of a blood glucose meter that uses a 10-test disk.  Diabetes Technology & Therapeutics, 6:495-502, 2004.

Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Garg S, Eckel RH, Rewers M:  Awareness and treatment of dyslipidemia in young adults with type 1 diabetes .  Diabetes Care, 28:1051-1056, 2005.

Garg SK:  Insulin glargine:  A True long-acting insulin analog.  Journal of Post Graduate Medicine, 2005.

Garg SK, Rosenstock J and Ways K: Optimized basal-bolus insulin regimen in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocrine Practice, 11:11-17, 2005.

Maahs DM, Kinney GJ, Wadwa P, Snell-Bergeon, Dabelea D, Hokanson JE, Ehrilch J, Garg    S, Eckel R, Rewers M: Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes and a comparable general population. Diabetes Care: 2005:28 (2), 301-306

Hirsch IB, Bode BW, Garg SK, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski J:       Continuous subcutaneous infusion of insulin aspart vs. multiple daily injection of insulin aspart/insulin glargine in type 1 diabetes.  Diabetes Care, 28: 533-538, 2005.

Izuora KE, Chase HP, Jackson WE, Coll JR, Osbert IM, Gottlieb PA, Rewers MJ, Garg SK:  Inflammatory markers and diabetic retinopathy in type 1 diabetes.  Diabetes Care, 28:714-715, 2005.

Garg SK, Ellis SL, Ulrich:  Insulin glulisine:  a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin. Pharmacother, 6(4)1-9, 2005.

Garg S:  New insulin analogues. Diabetes Technology & Therapeutics, 7:811-815, 2005.

Garg SK, Rosenstock J, Silverman B, Sun B, Konkoy CS, de la Pena A, Muchmore DB:  Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.  Diabetologia, 49:891-899, 2006.

Maahs DM, Snell-Bergeron JK, Kinney GL, Wadwa RP, Garg S, Ogden LG, Rewers M:  Treatment of albuminuria in type 1 diabetes patients is associated with lower odds of progression of coronary artery calcification.  Diabetalogia, 2005.

Dixon B, Chase HP, Burdick J, fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK:  Use of insulin glargine in children under age 6 with type 1 diabetes.  Pediatric Diabetes, 6:150-154, 2005.

Garg, SK, Zisser, H., Schwartz, S., Bailey, T., Kaplan, R., Ellis, S., Jovanovic, L:  Improvement in Glycemic Control with a Transcutaneous, Real-Time Continuous Glucose Sensor:  Randomized Controlled Trial:  Diabetes Care, 29:44-50, 2006.

Garg SK, Hirsch IB, Dailey G:  Practical strategies for introducing insulin therapy in 2006.  Journal of Family Practice, Clinical Update, S1-S12, April 2006

Kretowski A, Hokanson JE, McFann K, Kinney GL, Snell-Bergeon JK, Maahs DM, Wadwa RP, Eckel RH, Ogden LG, Garg SK, Li J, Cheng S, Erlich HA, Rewers M:  Gln360His Polymorphism of apolipoprotein A-IV predicts progression of coronary artery calcification in patients with type 1 diabetes. Diabetaolgia, 49:1946-1954, 2006.

Garg SK, Ulrich HC:  Achieving goal A1c in diabetes mellitus:  Practical strategies for success with insulin therapy. Insulin, 1:109-121, 2006.

Hirsch IB, Blonde L, Buse J, Close K, Edelman S, Peters A, Valentine V, Wysham C, Garg S:  Consensus development of conference on pramlintide in the management of type 1 and type 2 diabetes.  Diabetes Care, June, 2006; 1-13.

Garg SK, Lavernia F, Levy P:  Insulin in Depth – Modern diabetes management scientific symposium report:  Highlights from the symposium held at the American College of Physicians Annual Session 2006, Philadelphia, Pennsylvania.  American College of Physicians, 1-7, April 2006.

Edelman SV, Garg SK, Frias JP, Maggs D, Wang Y, Strobel SA, Lutz K, Kolterman OG:  A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.  Diabetes Care, 29:2189-2195, 2006.

Garg S, Jovanovic L:  Clinical Trial of a seven-day continuous glucose sensor demonstrates the importance of fasting hyperglycemia and the dawn phenomenon.  Diabetes Care, 29:2644-2649, 2007.

S. Garg:  Author’s reply on “Improved glycemic excursions with glucose sensing” by Chantal Mathieu.  International Diabetes Monitor, 19:38, 2007.

Kretowski A, McFann K, Hokanson JE, Maahs D, Kinney G, Snell-Bergeon J, Wadwa RP, Eckel RH, Ogden L, Garg S, Li J, Cheng S, Erlich HA, Rewers M:  Polymorphisms of the Renin-Antiotensin system genes predict progression of subclinical atherosclerosis.  Diabetes, 56:863-871, 2007.

Garg SK, Bailey TS, Zisser H:  Reduction in Hemoglobin A1c with Real-Time Continuous Glucose Monitoring: Results From a 12-Week Study.  Diabetes Technology & Therapeutics, 2007.

Bookout T, Ellis S, Garg S:  Continuous glucose monitoring.  Current Diabetes Reviews, 2007.

Ellis S, Gemperline K, Garg S:  Using continuous glucose monitoring to improve diabetes management.  Clinics in North America (Supplement), 2007.